伊布替尼单药治疗难治复发性B细胞淋巴瘤3例并文献复习

王莹; 闫志凌; 李护君; 张焕新; 祁岳坤; 田宇; 李振宇; 徐开林

doi:10.13201/j.issn.1004-2806.2020.09.012

伊布替尼单药治疗难治复发性B细胞淋巴瘤3例并文献复习

- 徐州医科大学附属医院血液科, 徐州医科大学血液病研究所(江苏徐州, 221002)
基金项目:
国家自然科学基金(No:81700177)

详细信息

通讯作者: 徐开林,E-mail:lihmd@163.com

中图分类号: R733.4

收稿日期: 2018-06-23

Single-agent Ibrutinib in the treatment of relapsed and refractory B cell lymphoma:three cases report and literature review

More Information

Corresponding author: XU Kailin, E-mail: lihmd@163.com

Received Date: 23 June 2018

摘要

- 伊布替尼 /
- BTK抑制剂 /
- B细胞淋巴瘤
Abstract: Bruton's tyrosine kinase (BTK),an important mediator of the BCR signal pathway,plays an important role in the formation of B-cell lymphoma.Ibrutinib is an oral active BTK inhibitor that effectively inhibits the malignant proliferation and induces apoptosis of B cells.As a single agent,it has shown extremely promising activity in relapsed and refractory B-cell lymphoma patients with well tolerability and acceptable toxicities.In our department,3 patients with relapsed and refractory B-cell lymphoma received single-agent Ibrutinib achieved remission in short time.
- Ibrutinib /
- Bruton tyrosine kinase inhibitor /
- B cell lymphoma

HTML全文

参考文献(15)

[1]	卜凡丹,刘新月.BTK抑制剂治疗套细胞淋巴瘤的研究进展[J].临床血液学杂志,2016,29(3):255-258.
[2]	王志清,徐祖琼,朱学军.新药治疗慢性淋巴细胞白血病的进展[J].临床血液学杂志,2016,29(7):604-608.
[3]	O'Brien S,Furman RR,Coutre SE,et al.Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma:an open-label,multicentre,phase 1b/2 trial[J].Lancet Oncol,2014,15:48-58.
[4]	O'Brien S,Furman RR,Coutre S,et al.Single agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia:a 5-year experience[J].Blood,2018,131:1910-1919.
[5]	Wang ML,Blum KA,Martin P,et al.Long-term follow-up of MCL patients treated with single-agent ibrutinib:updated safety and efficacy results[J].Blood,2015,126:739e45.
[6]	Dreyling M,Jurczak W,Jerkeman M,et al.Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma:an international,randomized,open-label,phase 3 study[J].Lancet,2016,387:770-778.
[7]	Dimopoulos MA,Trotman J,Tedeschi A,et al.Ibrutinib for patients with rituximab-refractory Walde-nström's macroglobulinaemia(iNNOVATE):an open-label substudy of an international,multicentre,phase 3 trial[J].Lancet Oncol,2017,18:241-250.
[8]	Noy A,de Vos S,Thieblemont C,et al.Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma[J].Blood,2017,129:2224-2232.
[9]	陈燕梅,裕丹.非生发中心弥漫大B细胞淋巴瘤研究进展[J].临床血液学杂志,2016,29(7):428-433.
[10]	Wilson WH,Young RM,Schmitz R,et al.Targeting B cell receptor signaling with Ibrutinib in diffuse large B cell lymphoma[J].Nat Med,2015,21:922-926.
[11]	Grommes C,Pastore A,Palaskas N,et al.Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma[J].Cancer Discov,2017,7:1018-1029.
[12]	Bartlett NL,Costello BA,LaPlant BR,et al.Single-agent ibrutinib in relapsed or refractory follicular lymphoma:a phase 2 consortium trial[J].Blood,2018,131:182-190.
[13]	Richardson PG,Bensinger WI,Huff CA,et al.Butinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma:phase 2 trial results[J].Br J Haematol,2018,180:821-830.
[14]	Mason C,Savona S,Rini JN,et al.Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome[J].Br J Haematol,2017,179:339-341.
[15]	Boudin L,Patient M,Roméo E,et al.Efficacy of ibrutinib as first-line treatment of tumoral Bing-Neel syndrome[J].Leuk Lymphoma,2018,59:2746-2748.